StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Fractyl Health Inc (GUTS)

Wed, 15 Jul 2026 12:16:24 -0400

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $8.00 price target on Fractyl Health Inc (NASDAQ: GUTS).

The analyst comments "Overall, we believe that REMAIN-1 midpoint cohort data demonstrate Revita-mediated durable and substantial weight retention at one year without the need for ongoing medication. We expect these observations to be reproduced and valudated in the ongoing, larger pivotal cohort of patients. Topline six-month randomized data are anticipated in 4Q26, and the company is targeting a De Novo marketing application submission in late 4Q26. We believe Revita is well-positioned to deliver meaningful clinical, regulatory, and commercial outcomes, and look forward

Morgan Stanley Reiterates Equalweight Rating on Fractyl Health Inc (GUTS)

Wed, 15 Jul 2026 12:15:22 -0400

Morgan Stanley analyst Michael E Ulz reiterated an Equalweight rating and $2.00 price target on Fractyl Health Inc (NASDAQ: GUTS)

The analyst comments "Greater benefit observed in patients receiving complete duodenal ablations. Fractyl reported one-year randomized data from the REMAIN-1 Midpoint Cohort (press release and presentation), supporting durability of Revita for post-GLP-1 weight maintenance ahead of pivotal data later this year. In the modified intentionto-treat population (mITT; n=45), a single Revita procedure reduced weight regain by ~40% versus sham at one year (7.8% vs. 13.0% body weight regained), while participants receiving complete duodenal ablation (>14 cm) maintained ~81% of their prior

Form 8-K FRACTYL HEALTH, INC. For: Jul 15

Wed, 15 Jul 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260715/26770354.html

Form 8-K FRACTYL HEALTH, INC. For: Jul 15

Wed, 15 Jul 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260715/26770354.html

Fractyl Health reports one-year weight maintenance data after GLP-1 stop

Wed, 15 Jul 2026 06:00:29 -0400

Fractyl Health, Inc. (Nasdaq: GUTS) released one-year results from the REMAIN-1 Midpoint Cohort, a randomized, double-blind, sham-controlled study evaluating its Revita DMR System for weight maintenance following discontinuation of GLP-1 therapy.

In the full modified intention-to-treat population of 45 participants, a single Revita procedure reduced weight regain by approximately 40% compared with sham at one year, with least-squares mean weight regain of 7.8% versus 13.0% of body weight. Participants who received complete duodenal ablation of more than 14 centimeters maintained approximately 81% of GLP-1-induced weight loss at one year, compared with 48% in sham participants.

In an optimized subgroup that received complete

Fractyl Health reports one-year weight maintenance data after GLP-1 stop

Wed, 15 Jul 2026 06:00:29 -0400

In an optimized subgroup that received complete

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Wed, 15 Jul 2026 06:00:00 -0400

Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations

Next anticipated Revita® milestones are topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026 and a potential FDA De Novo marketing application submission in late Q4 2026

Company to host investor webcast today at 8:00 a.m. ET

BURLINGTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Wed, 15 Jul 2026 06:00:00 -0400

Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations

Company to host investor webcast today at 8:00 a.m. ET

BURLINGTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel

Craig-Hallum Starts Fractyl Health Inc (GUTS) at Buy

Wed, 01 Jul 2026 09:14:12 -0400

(Updated - July 1, 2026 9:14 AM EDT)

Craig-Hallum analyst Chase Knickerbocker initiates coverage on Fractyl Health Inc (NASDAQ: GUTS) with a Buy rating and a price target of $4.00.

The analyst comments "Fractyl is developing a procedure-based approach for obesity, specifically targeting the emerging need for durable weight maintenance following GLP-1 discontinuation. Over half of patients who start GLP-1 therapy discontinue within a year, in large part due to tolerability issues. This creates a large unmet need: we believe ~20M adults are currently on GLP-1s in the U.S., and that number is expected to grow substantially. This presents a substantial opportunity

Craig-Hallum Starts Fractyl Health Inc (GUTS) at Buy

Wed, 01 Jul 2026 09:14:12 -0400

(Updated - July 1, 2026 9:14 AM EDT)

Craig-Hallum analyst Chase Knickerbocker initiates coverage on Fractyl Health Inc (NASDAQ: GUTS) with a Buy rating and a price target of $4.00.

Form 4 FRACTYL HEALTH, INC. For: Jun 12 Filed by: Royan Ajay

Mon, 15 Jun 2026 18:07:00 -0400

si-local-file:///var/storage/secattach/20260615/26648863.html

Form 4 FRACTYL HEALTH, INC. For: Jun 12 Filed by: Royan Ajay

Mon, 15 Jun 2026 18:07:00 -0400

si-local-file:///var/storage/secattach/20260615/26648863.html

Form 8-K FRACTYL HEALTH, INC. For: Jun 10

Thu, 11 Jun 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260611/26636772.html

Form 8-K FRACTYL HEALTH, INC. For: Jun 10

Thu, 11 Jun 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260611/26636772.html

Form 4 FRACTYL HEALTH, INC. For: Jun 10 Filed by: BRADLEY WILLIAM

Thu, 11 Jun 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260611/26636685.html

Form 4 FRACTYL HEALTH, INC. For: Jun 10 Filed by: BRADLEY WILLIAM

Thu, 11 Jun 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260611/26636685.html

Form 4 FRACTYL HEALTH, INC. For: Jun 10 Filed by: Conaway Samuel

Thu, 11 Jun 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260611/26636674.html

Form 4 FRACTYL HEALTH, INC. For: Jun 10 Filed by: Conaway Samuel

Thu, 11 Jun 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260611/26636674.html

Form 4 FRACTYL HEALTH, INC. For: Jun 10 Filed by: Thompson Christopher Charles

Thu, 11 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260611/26636660.html

Form 4 FRACTYL HEALTH, INC. For: Jun 10 Filed by: Thompson Christopher Charles

Thu, 11 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260611/26636660.html

Form 4 FRACTYL HEALTH, INC. For: Jun 10 Filed by: Royan Ajay

Thu, 11 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260611/26636664.html

Form 4 FRACTYL HEALTH, INC. For: Jun 10 Filed by: Royan Ajay

Thu, 11 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260611/26636664.html

Form 4 FRACTYL HEALTH, INC. For: Jun 10 Filed by: Barnes Kelly Ann

Thu, 11 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260611/26636653.html

Form 4 FRACTYL HEALTH, INC. For: Jun 10 Filed by: Barnes Kelly Ann

Thu, 11 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260611/26636653.html

Form 4 FRACTYL HEALTH, INC. For: Jun 10 Filed by: Elia Marc

Thu, 11 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260611/26636654.html